Navigation Links
Replication in Biological Technology

Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data

... understanding of the protein chemistry of rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains prior to an ... a new group of peptides related to the rapid replication function in viral and other diseases. The company ...

Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak

... successfully block the entry of H5N1 virus into, replication in, and excretion from chickens. The company is ... a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been ... produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. ...

Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak

... successfully block the entry of H5N1 virus into, replication in, and excretion from chickens. Another ... a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been ... produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. ...

Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer

... agents which constitute the portfolio target the replication of the human immunodeficiency virus (HIV), human ... with the FDA. The compounds inhibit virus replication by a highly unique mechanism of action involving ... disease by targeting a critical viral replication pathway within the infected cell and turning off ...

Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes

... this study, trypanosomes have one of the highest replication rates in nature. This property may account in ... of the relation of the replikins to rapid replication offers a new approach, and the means, to inhibit rapid replication and limit mortality in malaria. Contact: ...

Lethality of H1N1 Influenza Virus Increasing According to Latest Analysis of Virus Peptide Genomic Data

... discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique ... on the company's discovery of a new group of peptides related to rapid replication called Replikins, whose increase in concentration in virus or other ...

Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic

... radiation. Simultaneously, a therapeutic cascade is initiated by product replication resulting in tumor vasculature shutdown and anti-tumoral immune attack. ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...

Purdue researcher invents molecule that stops SARS

... Ind. - A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the ... specific protein, called papain-like protease, or PLpro, involved in viral replication and evasion of the immune system," said Ghosh who has a joint appointment ...

NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate

... evaluated as controls. The VLP-immunized mice were protected from RSV replication in the lungs. Further, the lung tissue of these mice showed no evidence ... induced strong antibody responses against RSV, protected mice against RSV replication in the lungs, and did not lead to enhanced inflammation of the airways. ...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

... Seek to Identify microRNAs Implicated in HIV Viral replication and Their Function Samples Will be Screened and Analyzed Using Rosetta ... the link between the aberrant expression of microRNAs and the viral replication of HIV, and to identify potential microRNA drug targets", said Dr. Zvi ...

Replidyne Announces Second Quarter 2008 Results From Operations

... discovery research programs, primarily the C. difficile and DNA replication inhibition programs, offset by decreased expense related to the REP8839 ... the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. The Company's ...

Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors

... to a new and potent class of integrase inhibitor drugs that blocks viral replication by preventing viral genes from integrating into the DNA of newly infected ... in the absence of drug, PhenoSense Integrase also provides a measure of replication capacity (RC) of integrase inhibitor sensitive and resistant viruses. ...

H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria

... A rising Replikin Count of a particular influenza strain, indicating rapid replication of the virus, is an early warning which has been followed consistently by ... to limit H5N1's ability to produce a pandemic. Furthermore, the H5N1 rapid replication cycle which began in 1996 now appears to be over. The H5N1 virus produced ...

Replidyne Announces 2007 Fourth Quarter and Full Year Results

... research programs, primarily its C. difficile and inhibition of DNA replication programs offset by decreased expense related to the REP8839 program that ... the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. Safe Harbor ...

FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over

... mortality characteristics are expected to subside - until the next rapid replication cycle of this or another influenza virus strain begins. 140,000 virus ... whose concentration has been shown to be related quantitatively to rapid replication and epidemics. FluForecast(R) is a product and service of Replikins Ltd. ...

International team identifies 480 genes that control human cell division

... of activation in cancer cells. Malignant cells have lost control of the replication process, so detecting differences in cell cycle gene activation in normal ... in Israel. Rather than cycling on and off as normally occurs when cell replication and development proceeds, these genes are expressed in a steady state or ...

Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent

... factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing. "This patent represents a ...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

... vaccine candidate in mice showed that it induced production of antibodies that neutralized live RSV. In addition, the vaccine protected mice against replication of RSV in the lungs. The study included groups of mice that received two injections of RSV-F vaccine at doses of 1, 10, or 30 micrograms with and ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... SPC3649-HCV SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and the Company ...

Cynvec to Present at The 2009 New York Venture Summit

... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and ...

Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry

... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

... Sanjay Goel and colleagues delivered a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live replication Competent RNA Virus in Patients with Advanced Solid Tumors." The results, which were previously announced in June 2007, demonstrated that REOLYSIN ...

Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference

... scheduled to deliver a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live replication Competent RNA Virus in Patients with Advanced Solid Tumors." About Oncolytics Biotech Inc. Oncolytics is a Calgary-based ...

Cynvec to Present at New York Biotechnology Association 18th Annual Meeting

... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre- clinical models of ovarian and ...

ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.

... screening efforts have identified ten pyrimidinediones as inhibitors of HBV replication, with two compounds yielding potent inhibition of HBV replication at sub-micromolar concentration levels. The two lead molecules, IQP-0568 and IQP-0589 have also been shown to be active non-nucleoside inhibitors of ...

Cynvec to Present at the BIO National Venture Conference

... CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and ...

Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates

... disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. In HCV care, the device inhibits viral replication through selective elimination of HCV in circulation and assists to preserve immune cells by removing toxic proteins shed from the surface of HCV. ...

AcroMetrix Announces the Release of OptiQuant-S Hepatitis C Virus (HCV) Panel

... RNA viruses like HCV or HIV. This new technology allows insertion of synthetic sequences into a mammalian RNA virus which were shown to be stable in replication and capable of forming infectious RNase resistant virus particles. This new proprietary system can be used for designing defined RNA positive ...

ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs

... For prevention, the lead pyrimidinedione exhibits characteristics of an ideal microbicide, including the inhibition of two early steps in the viral replication pathway as well as its lack of toxicity to the cells and normal bacterial flora of the vaginal microenvironment. Nick Kaludov, Ph.D. (Director, ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. ...

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey replication (NCS-R). Archives of General Psychiatry , 2005 Jun; 62(6):617-27. ...

ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections

... that IQP-0410 is well tolerated and safe with plasma drug concentrations 10-20-fold greater than those required for complete suppression of HIV replication at 24-hours following oral administration. Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile which suggests it ...

Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1

... knowledge, the first quantitative measures of virus structural change ever shown to correlate with and to precede virus outbreaks. Cycles of rapid replication of the virus with increasing replikin counts appear to be a means of virus expansion into new host populations and geographic areas, and of ...

Jennerex Appoints Samantha Miller as Vice President of Corporate Development

... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...

LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates

... into the constituent proteins that make up infectious virus particles. Anti-AIDS drugs targeting HIV-1 protease substantially suppress HIV viral replication and dramatically reduce mortality among HIV infected patients. Beta-Secretase (BACE-1) has been identified as a key enzyme that mediates a critical ...

GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.

... for hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com . Cowen and Company was the exclusive financial advisor to ...

deCODE genetics Announces Third Quarter 2008 Financial Results

... by deCODE and others, contribute to the incidence of an estimated 60 percent of all breast cancers. The test integrates data from discovery and replication studies published in major peer-reviewed journals and involving nearly 100,000 breast cancer patients and healthy volunteers from many ...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008

... Medical Officer of Romark Laboratories. -- "Potential Role for Nitazoxanide in Combination with STAT-C Agents for the Inhibition of HCV replication Without the Development of Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session #115) This oral presentation by Brent ...

GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C

... candidate for hepatitis E partnered with GSK, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com . Cowen and Company was the exclusive financial advisor to ...
Other Contents
(Date:9/30/2014)... Institutes of Health (NIH) awarded Lawrence Livermore National ... electrode array system that will enable researchers to ... resolution and scale. , LLNL,s grant-funded project is ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... our understanding of the human mind and uncover ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... for doctors to measure damaging "brain tsunamis" in ... a step closer to reality, thanks to pioneering ... Institute. , The research team, led by Jed ... of neurosurgery at the UC College of Medicine, ... through an injured brain like tsunami wavescan be ...
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new ... at higher rates than other primary care practices ... according to results of a new 10-state University ... Medical Care . , Using data from a ... 2013, the investigators found that FQHCs community ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered by ... a free book and class all about survival education and ... investigative review. , “Joe Marshall of SurvivalLife.com is one ... niche, and this product is an excellent way to get ... that Joe offers on his website to help people be ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2
Other TagsOther Tags